Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
atorvastatin + interferon beta + erythropoietin
- Development stage
- Unknown
- Lead developer
- Sun Yat-sen University
- Modality
- Recombinant Proteins and Enzymes, Small Molecules
- Administration
- Oral, Intramuscular, Subcutaneous
01
Overview
This combination therapy regimen, comprising atorvastatin, interferon beta, and erythropoietin (EPO), was investigated by Sun Yat-sen University for the treatment of multiple sclerosis (MS) and neuromyelitis optica (NMO). Atorvastatin is an HMG-CoA reductase inhibitor included for its potential immunomodulatory and neuroprotective effects. Interferon beta is a standard disease-modifying therapy for MS that modulates the immune response to reduce relapse frequency. Erythropoietin, a glycoprotein hormone traditionally used to treat anemia, is explored in this context for its neuroprotective, anti-apoptotic, and anti-inflammatory properties within the central nervous system. The triple combination aims to leverage synergistic mechanisms to improve clinical outcomes and stabilize disease progression in Chinese patient populations.
- Other names
- EPO + atorvastatin + beta-interferonerythropoietin + atorvastatin + interferon beta
02
Targets
Erythropoietin ReceptorIFNAR (Immune system modulation via type I interferon receptor)HMGCR (3-hydroxy-3-methylglutaryl-coenzyme A reductase)
Beyond the preview
Go deeper on atorvastatin + interferon beta + erythropoietin.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on atorvastatin + interferon beta + erythropoietin.